Literature DB >> 8520090

Use of confidence intervals and sample size calculations in health economic studies.

J A Sacristán1, S J Day, O Navarro, J Ramos, J M Hernández.   

Abstract

OBJECTIVE: To discuss the calculation and application of confidence intervals in pharmacoeconomic studies. DATA SYNTHESIS: The increasing frequency with which pharmacoeconomic evaluations are made within clinical trials makes it possible to obtain information on the outputs and costs of an intervention in each patient of a sample under study. This allows the same statistical principles commonly used in clinical trials to be applied to cost or cost-effectiveness data. The methodology described in this article would allow expression of cost-effectiveness ratios in the form of confidence intervals. The calculation of the cost-effectiveness ratio by means of a confidence interval may have important practical consequences, both in decision-making on the choice of 1 intervention versus another and in calculating the size of the sample necessary to identify statistically significant differences, from both clinical and economic points of view.
CONCLUSIONS: The complementary use of confidence intervals and sensitivity analysis makes it possible to measure uncertainty related and unrelated to variability in sample data, allowing the decision to adopt 1 technology or another to be based on the most objective information available. Although several ethical and methodologic concerns remain to be addressed, this methodology may contribute to improving the more rational and efficient use of drugs.

Entities:  

Mesh:

Year:  1995        PMID: 8520090     DOI: 10.1177/106002809502907-815

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  9 in total

Review 1.  Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.

Authors:  D A Revicki; L Frank
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 2.  Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

Authors:  A O'Hagan; J W Stevens; J Montmartin
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

3.  Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature.

Authors:  K E Agro; C A Bradley; N Mittmann; M Iskedjian; A L Ilersich; T R Einarson
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

4.  Use of confidence intervals in health economic studies.

Authors:  J A Sacristán
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

5.  Cost-effectiveness acceptability curves revisited.

Authors:  Maiwenn J Al
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

6.  Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy.

Authors:  R L Obenchain; C A Melfi; T W Croghan; D P Buesching
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

7.  Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.

Authors:  A Messori; S Trippoli; P Becagli; G Zaccara
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

8.  Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.

Authors:  S J Ackerman; E M Sullivan; K M Beusterien; H M Natter; D F Gelinas; D L Patrick
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

9.  Protocol for north of England and Scotland study of tonsillectomy and adeno-tonsillectomy in children (NESSTAC). A pragmatic randomised controlled trial comparing surgical intervention with conventional medical treatment in children with recurrent sore throats.

Authors:  John Bond; Janet Wilson; Martin Eccles; Alessandra Vanoli; Nick Steen; Ray Clarke; Andrew Zarod; Catherine Lock; Katie Brittain; Chris Speed; Nikki Rousseau
Journal:  BMC Ear Nose Throat Disord       Date:  2006-08-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.